RYTM Stock Analysis: Buy, Sell, or Hold?
RYTM - Rhythm Pharmaceuticals, Inc. Common Stock
$102.52
-1.18 (-1.14%)
▼
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 25, 2026
22d
Get Alerted When RYTM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RYTM shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: RYTM shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: RYTM is currently trading at $102.52, which is considered slightly low relative to its 30-day fair value range of $101.08 to $108.98.
Technical Outlook: Technically, RYTM is in a uptrend. Immediate support is located at $99.10, while resistance sits at $109.02.
Market Sentiment: RYTM has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $141.57 (+38.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RYTM is in a uptrend. Immediate support is located at $99.10, while resistance sits at $109.02.
Market Sentiment: RYTM has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $141.57 (+38.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$101.08 -
$108.98
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 38.1% below Wall St target ($141.57)
Fair Price Analysis
30-Day Fair Range
$101.08 -
$108.98
Current vs Fair Value
SLIGHTLY LOW
Expected Move (7 Days)
±$9.37
(9.1%)
Support & Resistance Levels
Support Level
$99.10
Resistance Level
$109.02
Current Trend
Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-39.14
Wall Street Target
$141.57
(+38.1%)
Revenue Growth (YoY)
54.3%
Profit Margin
-110.3%
Last updated: February 01, 2026 7:10 PM ET
Data refreshes hourly during market hours. Next update: 8:10 PM
Data refreshes hourly during market hours. Next update: 8:10 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RYTM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Joseph Shulman
SELL
14437 shares
2025-10-16
Joseph Shulman
SELL
4188 shares
2025-08-21
Hunter C Smith
SELL
3477 shares
2025-08-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$56 | 59 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$213 | 57 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
|
ARVN
Arvinas Inc |
BUY
21 analysts |
$13 | 63 BUY |
Advanced RYTM Option Strategies
Professional options setups generated by AI based on today's RYTM price and gamma walls.
